Apremilast, a novel small mol. inhibitor of PDE4. Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis. Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types. As this novel PDE4 inhibitor interferes with several key processes of inflammation, Apremilast may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints.
ChemScene can order timely high quality and efficient services of various compounds from mg to kg level for some clients' bioscience research. We are committed to researching and developing reference compounds with high synthesis technology barriers and difficulties. ChemScene also has a tradition of working with scientists to bring new discoveries out of the laboratory and into the commercial arena.
View more >>
United States
China 
![CAS No:608141-41-9 N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,<br />3-dioxoisoindol-4-yl]acetamide](/structure/cas-608/608141-41-9.png)